Summary
EudraCT Number: 2005-004048-30
Sponsor's Protocol Code Number: 
National Competent Authority: Finland - Fimea 
Clinical Trial Type: EEA CTA
Trial Status: Ongoing
Date on which this record was first entered in the EudraCT database: 2005-09-23
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004048-30/FI/

A. Protocol Information
A.1 Member State Concerned: Finland - Fimea
A.2 EudraCT number: 2005-004048-30
A.3 Full title of the trial: Raskausdiabeteksen lääkehoito
A.4.1 Sponsor's protocol code number: 
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Turku Univeristy Hospital
B.1.3.4	Country: Finland
B.3.1 and B.3.2	Status of the sponsor: Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.1.1.1 Trade name: Diformin retard

D.2.1.1.2 Name of the Marketing Authorisation holder: Leiras, Finland
D.2.1.2 Country which granted the Marketing Authorisation: Finland
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: Information not present in EudraCT
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: metformiini
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Information not present in EudraCT
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: Information not present in EudraCT
D.3.11.3.2 Gene therapy medical product: Information not present in EudraCT
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: Information not present in EudraCT
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): Information not present in EudraCT
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: Information not present in EudraCT
D.3.11.11 Herbal medicinal product: Information not present in EudraCT
D.3.11.12 Homeopathic medicinal product: Information not present in EudraCT
D.3.11.13 Another type of medicinal product: Information not present in EudraCT
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.1.1.1 Trade name: Protaphane Flexpen
D.2.1.1.2 Name of the Marketing Authorisation holder: Novo Nordisk
D.2.1.2 Country which granted the Marketing Authorisation: Finland
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Injection*
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Subcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: isofaani-insuliini
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Information not present in EudraCT
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: Information not present in EudraCT
D.3.11.3.2 Gene therapy medical product: Information not present in EudraCT
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: Information not present in EudraCT
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): Information not present in EudraCT
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: Information not present in EudraCT
D.3.11.11 Herbal medicinal product: Information not present in EudraCT
D.3.11.12 Homeopathic medicinal product: Information not present in EudraCT
D.3.11.13 Another type of medicinal product: Information not present in EudraCT
D.IMP: 3
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.1.1.1 Trade name: Novorapid Flexpen
D.2.1.1.2 Name of the Marketing Authorisation holder: Novo Nordisk
D.2.1.2 Country which granted the Marketing Authorisation: Finland
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Injection*
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Subcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: aspartinsuliini
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Information not present in EudraCT
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: Information not present in EudraCT
D.3.11.3.2 Gene therapy medical product: Information not present in EudraCT
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: Information not present in EudraCT
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): Information not present in EudraCT
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: Information not present in EudraCT
D.3.11.11 Herbal medicinal product: Information not present in EudraCT
D.3.11.12 Homeopathic medicinal product: Information not present in EudraCT
D.3.11.13 Another type of medicinal product: Information not present in EudraCT
D.IMP: 4
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.1.1.1 Trade name: Humalog Pen
D.2.1.1.2 Name of the Marketing Authorisation holder: Eli Lilly Finland
D.2.1.2 Country which granted the Marketing Authorisation: Finland
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Injection*
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Subcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: lisproinsuliini
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Information not present in EudraCT
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: Information not present in EudraCT
D.3.11.3.2 Gene therapy medical product: Information not present in EudraCT
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: Information not present in EudraCT
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): Information not present in EudraCT
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: Information not present in EudraCT
D.3.11.11 Herbal medicinal product: Information not present in EudraCT
D.3.11.12 Homeopathic medicinal product: Information not present in EudraCT
D.3.11.13 Another type of medicinal product: Information not present in EudraCT

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Raskausdiabetes
MedDRA Classification
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: Verrata metformiini- ja insuliinihoitoa lievässä, mutta lääkehoitoa vaativassa raskausdiabeteksessa vastasyntyneen voinnin kannalta.
E.2.2 Secondary objectives of the trial: Verrata metformiini- ja insuliinihoitoa lievässä, mutta lääkehoitoa vaativassa raskausdiabeteksessa raskaus- ja synnytyskomplikaatioiden kannalta.
E.2.3 Trial contains a sub-study: Information not present in EudraCT
E.3 Principal inclusion criteria: Lääkehoitoa vaativa raskausdiabetes.
E.4 Principal exclusion criteria: Metformiini- tai insuliinihoito aloitettu ennen keskiraskautta.
Verensokeri niin korkea, että insuliinihoito on välttämätön.

E.5 End points
E.5.1 Primary end point(s): Lapsen kunto periantaali- ja neonataalivaiheessa:
- syntymäpaino suhteessa gestaatioikään
- hypoglykemia ja sen kesto
- keuhkojen toiminta


E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): Yes
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Yes
E.8.2.2 Placebo: No
E.8.2.3 Other: Yes
E.8.2.3.1 Comparator description: insuliinit
E.8.3 The trial involves single site in the Member State concerned: Yes
E.8.4 The trial involves multiple sites in the Member State concerned: No
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: Information not present in EudraCT
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: Tutkimus loppuu, kun molemmissa hoitoryhmissä on synnyttännyt 139 äitiä ja lapset saavuttaneet yhden vuoden iän.
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 4
E.8.9.1 In the Member State concerned months: 
E.8.9.1 In the Member State concerned days: 

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): No
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: No
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Information not present in EudraCT
F.3.3.1 Women of childbearing potential not using contraception  
(For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and
did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether
or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the
database on 2005-09-23) : Yes
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: Yes
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 278
F.4.2 For a multinational trial
F.4.2.2 In the whole clinical trial: 278
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition): normal treatment

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2005-11-29
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2005-11-11

P. End of Trial
P. End of Trial Status: Ongoing

